FDA Approves New Indication For Roferon-A in CML Patients

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

ROCKVILLE, Md--The Food and Drug Administration has approved a new indication for Roche Laboratories' Roferon-A (interferon alfa-2A recombinant). The agent, previously approved for use in treating hairy cell leukemia and AIDS-related Kaposi's sarcoma, is now also indicated for the treatment of chronic phase, Philadelphia chromosome positive chronic myelogenous leukemia (CML).

ROCKVILLE, Md--The Food and Drug Administration has approved anew indication for Roche Laboratories' Roferon-A (interferon alfa-2Arecombinant). The agent, previously approved for use in treatinghairy cell leukemia and AIDS-related Kaposi's sarcoma, is nowalso indicated for the treatment of chronic phase, Philadelphiachromosome positive chronic myelogenous leukemia (CML).

The treatment is intended for patients who have been either previouslyuntreated or minimally pretreated, preferably within 1 year fromdiagnosis.

"Roferon-A will provide many CML patients with another treatmentalternative, especially those for whom bone marrow transplantationis not an option," said Robert Armstrong, vice president,Medical Affairs, Roche Laboratories.

In a randomized study supporting the new indication, Roferon-Atherapy significantly prolonged the median survival of CML patientsby 14 months, compared with conventional chemotherapy, eitherhydroxyurea or busulfan (69 months in the Roferon-A arm vs 55months for conventional single-agent chemotherapy). In this trial,intermittent single-agent chemotherapy was allowed for insufficienthematologic response to Roferon-A alone, and 44% of the Roferon-Atreated patients also received this therapy at some time duringthe study.

Cytogenetic Responses

In addition, Roferon-A treatment slowed disease progression andelicited a higher cytogenetic response (disappearance of the Philadelphiachromosome) than did conventional treatment.

Patients with partial hematologic response should be treated forat least 18 months to maximize the possibility of a complete response,the company said. Treatment with Roferon-A should be continueduntil disease progression. Achievement of complete cytogeneticresponse has been observed up to 2 years following the start oftreatment with Roferon-A.

The FDA's recommended dosage of Roferon-A for treatment of CMLis 9 million IU administered daily as a subcutaneous or intramuscularinjection.

The most common side effects associated with the agent are fever,fatigue, myalgia, and chills, and 23% of patients were withdrawnfrom the randomized CML study because of these effects.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Related Content